1 of 1
Story summary
- On April 2, 2026, U.S. President Donald Trump announced agreements with 16 pharmaceutical companies to align U.S. drug prices with those in other developed nations.
- Companies like Pfizer and Novo Nordisk committed to significant price reductions in exchange for three-year tariff exemptions.
- Discounts of up to 85% on medications, including insulin and obesity treatments, were promised through the new platform TrumpRx.gov.
- Roche and Novartis also agreed to lower prices and provide drugs directly to consumers, while Regeneron has not yet finalized an agreement.
